All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% PDL1 < 25% PDL1 >25% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic-recurrent HNSCC (mHNSCC), durvalumab alone vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EAGLE (D vs ICC), 2019 0.88 [0.72; 1.08]
0.88 [0.72 ; 1.08 ] EAGLE (D vs ICC), 2019 1 0% 489 NA not evaluable progression or deaths (PFS)detailed results EAGLE (D vs ICC), 2019 1.02 [0.84; 1.24]
1.02 [0.84 ; 1.24 ] EAGLE (D vs ICC), 2019 1 0% 489 NA not evaluable DCRdetailed results EAGLE (D vs ICC), 2019 1.00 [0.63; 1.58]
1.00 [0.63 ; 1.58 ] EAGLE (D vs ICC), 2019 1 0% 489 NA not evaluable objective responses (ORR)detailed results EAGLE (D vs ICC), 2019 1.05 [0.66; 1.68]
1.05 [0.66 ; 1.68 ] EAGLE (D vs ICC), 2019 1 0% 489 NA not evaluable AE (any grade)detailed results EAGLE (D vs ICC), 2019 0.45 [0.21; 0.94]
0.45 [0.21 ; 0.94 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable AE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.89 [0.62; 1.28]
0.89 [0.62 ; 1.28 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable AE leading to death (grade 5)detailed results EAGLE (D vs ICC), 2019 1.01 [0.52; 1.97]
1.01 [0.52 ; 1.97 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results EAGLE (D vs ICC), 2019 0.97 [0.53; 1.77]
0.97 [0.53 ; 1.77 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable SAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.21 [0.80; 1.80]
1.21 [0.80 ; 1.80 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable STRAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.16 [0.56; 2.38]
1.16 [0.56 ; 2.38 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE (any grade)detailed results EAGLE (D vs ICC), 2019 0.29 [0.19; 0.45]
0.29 [0.19 ; 0.45 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.35 [0.21; 0.59]
0.35 [0.21 ; 0.59 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE leading to death (grade 5)detailed results EAGLE (D vs ICC), 2019 8.22 [0.43; 156.41]
8.22 [0.43 ; 156.41 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE leading to discontinuation (any grade)detailed results EAGLE (D vs ICC), 2019 0.91 [0.36; 2.28]
0.91 [0.36 ; 2.28 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Alopecia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Anaemia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.04 [0.00; 0.75]
0.04 [0.00 ; 0.75 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Asthenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
0.50 [0.05 ; 5.60 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
0.17 [0.01 ; 3.35 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
0.17 [0.01 ; 3.35 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Fatigue TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.14; 7.25]
1.01 [0.14 ; 7.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
1.01 [0.06 ; 16.29 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.12 [0.01; 2.37]
0.12 [0.01 ; 2.37 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.51 [0.02; 15.13]
0.51 [0.02 ; 15.13 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Nausea TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
2.03 [0.07 ; 60.79 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.04 [0.00; 0.68]
0.04 [0.00 ; 0.68 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
0.50 [0.05 ; 5.60 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Pruritus TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Rash TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
2.03 [0.07 ; 60.79 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
1.01 [0.06 ; 16.29 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 07:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 374